Report
How Regulatory Changes Are Driving The Future Of The Medical Device Industry
With new entrants from emerging countries giving the established brands a run for their money, the medical device market has become more competitive. ...
White paper
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...
White paper
Growing Attention Being Paid To Pharma Company Rebates And Discounts
Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...
White paper
Perspectives On Pharma Company Use Of Open Payments Data
This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...
White paper
How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?
The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...
White paper
Is The CVS-Aetna Merger A Pharma Industry Transformative Event?
US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...
White paper
Deploying Successful Global Incentive Compensation Capabilities
There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...
Article
The Causes and Solutions of Chronic Drug Shortages in the United States
While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...
White paper
Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape
With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...
White paper
The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics
Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...
White paper
Evolution of Pharmaceutical Call Planning
This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...
White paper
Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary
No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...
White paper
How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?
The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...
White paper
Is The CVS-Aetna Merger A Pharma Industry Transformative Event?
US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...
White paper
The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics
Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...
White paper
Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary
No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...
Industry Survey
State Of Commercial Excellence 2017 – Part 1
Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...
White paper
Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?
The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...
Whitepaper
Make US Pharma Great Again!? – Part 2
Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...
White paper
Make US Pharma Great Again!? – Part 1
The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...
White paper
Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics
The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...
Blog
Biosimilars In The US – Will They Deliver On The Promise?
Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...
White paper
The Pricing Challenge Of Pharma’s Shift To Specialty Medicines
The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift ...
White paper
Improve STAR Rating With Analytics Powered Therapy Adherence Strategy
Improving the quality of care and services to patients and enrollees is one of the key imperatives of Affordable Care Act (ACA). Several initiatives and measures have been put in p ...
White paper
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...
White paper
Growing Attention Being Paid To Pharma Company Rebates And Discounts
Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...
White paper
Perspectives On Pharma Company Use Of Open Payments Data
This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...
White paper
How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?
The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...
White paper
Is The CVS-Aetna Merger A Pharma Industry Transformative Event?
US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...
White paper
Deploying Successful Global Incentive Compensation Capabilities
There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...
Article
The Causes and Solutions of Chronic Drug Shortages in the United States
While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...
White paper
Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape
With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...
White paper
The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics
Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...
White paper
Evolution of Pharmaceutical Call Planning
This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...
White paper
Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary
No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...
White paper
Achieving Sales Operations Excellence With Intelligent Roster Management
Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...
Report
How Regulatory Changes Are Driving The Future Of The Medical Device Industry
With new entrants from emerging countries giving the established brands a run for their money, the medical device market has become more competitive. ...
White paper
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...
White paper
Growing Attention Being Paid To Pharma Company Rebates And Discounts
Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...
White paper
Perspectives On Pharma Company Use Of Open Payments Data
This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...
White paper
How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?
The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...
White paper
Is The CVS-Aetna Merger A Pharma Industry Transformative Event?
US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...
White paper
The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics
Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...
White paper
Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary
No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...
White paper
Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes
The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...
White paper
Decision Science Asset Diversification Versus Concentration
The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...
White paper
The Reasons for and Solutions to Chronic Drug Shortages in the United States
This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...
White paper
Pricing and Market Effects of Biosimilar Entry in the US
This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...